Nilotinib-Induced Keratosis Pilaris
Nilotinib is a second-generation Bcr-Abl tyrosine kinase inhibitor (TKI) that is approved for the treatment of imatinib-resistant chronic myeloid leukaemia expressing the Bcr-Abl mutation. Cutaneous adverse drug reactions occur more frequently in patients using this medication. We present a case of...
Shranjeno v:
| Main Authors: | , |
|---|---|
| Format: | Knjiga |
| Izdano: |
Karger Publishers,
2016-04-01T00:00:00Z.
|
| Teme: | |
| Online dostop: | Connect to this object online. |
| Oznake: |
Označite
Brez oznak, prvi označite!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Kopija 1 | Prosto |